From the Research
False Positive Rate of Signatera Test
- The false positive rate of the Signatera (circulating tumor DNA) test is not directly stated in the provided studies.
- However, study 1 mentions that five of the 122 nonrelapsed patients (all hormone receptor-positive) had an occasional positive test, suggesting a potential false positive rate.
- Study 2 does not provide information on the false positive rate of the Signatera test.
- Study 3 does not provide information on the false positive rate of the Signatera test.
- Study 4 does not provide information on the false positive rate of the Signatera test.
Related Information
- Study 1 reports a patient-level sensitivity of 88.2% for the Signatera test in detecting molecular relapse in patients with breast cancer.
- Study 5 discusses the potential of circulating tumor DNA (ctDNA) copy number variant detection for cancer screening, but does not provide information on the false positive rate of the Signatera test.
- Study 2 reports a 100% sensitivity of the Signatera test in detecting recurrence in patients with gastrointestinal cancers.
- Study 3 reports a significant association between ctDNA positivity and disease progression in patients with head and neck squamous cell carcinoma.
- Study 4 reports that ctDNA detection preceded the clinical diagnosis of recurrence by a median of 9 weeks in patients with metastatic colorectal cancer.